Clinical outcomes of radiation therapy

Prostate cancer can be a serious disease, but most men diagnosed with prostate cancer do not die from it.1 In fact, prostate cancer has a 98% relative survival rate at 5 years when combining all stages of diagnosis.2 If you’ve been diagnosed with prostate cancer, you and your physician may consider radiation therapy with SpaceOAR™ Hydrogel to help minimize potential side effects. Learn more about the clinical outcomes of radiation therapy and work with your physician to find the treatment that’s right for you.

Common Types of Radiation Therapy

 

EBRT has an on overall survival rate of 98.8% at the five-year mark.3

Seven years after treatment, patients had a 95% relapse-free survival rate.4

At three years, low-to-intermediate risk patients had a 94% survival rate and a 89.7% survival rate at five years

Five years after treatment low-risk patients had a 99% survival rate.6

While these are common types of radiation therapy for prostate cancer, they may not be available everywhere or best for every patient. Research all of your options on the American Cancer Society website at cancer.org, and choose the best treatment option based on the guidance of your healthcare provider.

Understanding your risk group

Your risk group is based on three factors: your Prostate Specific Antigen (PSA) score, your Gleason score, and the clinical stage of your prostate cancer.7

Low Risk

PSA less than 10
and
Gleason Score less than 7
and
Clinical Stage is T1c to T2a

Intermediate Risk

PSA  greater than 10 less than 20
or
Gleason Score is 7
or
Clinical Stage is T2b

High Risk

PSA greater than 20
or
Gleason Score is 8 to 10
or
Clinical Stage is T2c to T3c

Your physician will evaluate your scores and determine your risk category and course of treatment.

Related articles

A PSA About PSA Levels: Tips to Reduce Your Risk of Prostate Cancer

Understanding Prostate Cancer: Diagnosing, Grading and Staging

1. American Cancer Society. Prostate Cancer Key Statistics. Accessed April 14, 2022. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

2. American Cancer Society. Prostate Cancer Survival Rates. Accessed April 14, 2022. https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/survival-rates.html

3. Targeting Cancer. Radiation therapy: effective for prostate cancer. Accessed October 27, 2021. https://www.targetingcancer.com.au/2015/02/radiation-therapy-95-effective-prostate-cancer/

4. Kotecha R, Yamada Y, Pei X, et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy. Jan-Feb 2013;12(1):44-9.

5. Hannan R, Tumati V, Xie X, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer—results from a multi-institutional clinical trial. Eur J Cancer. 2016 May;59;142-51.

6. Mendenhall NP, Hoppe BS, Nichols RC. Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602.

7. Prostate Cancer Free. Prostate cancer risk groups: have you determined your risk group? Accessed October 10, 2021. https://www.prostatecancerfree.org/prostate-cancer-risk-groups/

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

SpaceOAR Hydrogel is intended to temporarily move the rectal wall away from the prostate during the course of radiotherapy treatment for prostate cancer, and in creating this space it is the intent of SpaceOAR Hydrogel to reduce the radiation dose affecting the rectum.

SpaceOAR Hydrogel contains polyethylene glycol (PEG). As with any medical treatment, there are some risks involved with the use of SpaceOAR Hydrogel. Potential complications associated with SpaceOAR Hydrogel include, but are not limited to: pain associated with injection, pain or discomfort from the hydrogel, site inflammation, infection (including abscess), inability to urinate, urgent need to urinate, constipation, rectal muscle spasm, damage to lining of rectum, ulcers, fistula (a hole between rectum and bladder, urethra, or skin below the scrotum), perforation (hole in prostate, bladder, urethra, rectum), necrosis (dead tissue), allergic reaction (local reaction or more severe reaction, such as anaphylaxis), embolism (blood vessel blockage is possible and may happen outside of the pelvis, potentially impacting vital organs or legs), fainting, and bleeding. Please talk to your doctor about the risks and benefits related to using SpaceOAR Hydrogel. If one or more of these complications occur, you may need medical treatment or surgery. URO-1288805-AA

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.

©2022 Boston Scientific Corporation or its affiliates. All rights reserved. URO-763108-AA MAY 2022